RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Guangdi Wang to Administration, Oral

This is a "connection" page, showing publications Guangdi Wang has written about Administration, Oral.
Connection Strength

0.335
  1. Guo S, Zhang C, Mottamal M, Hossain A, Liu J, Wang G. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models. Breast Cancer Res Treat. 2020 Apr; 180(2):359-368.
    View in: PubMed
    Score: 0.177
  2. Liu J, Zheng S, Akerstrom VL, Yuan C, Ma Y, Zhong Q, Zhang C, Zhang Q, Guo S, Ma P, Skripnikova EV, Bratton MR, Pannuti A, Miele L, Wiese TE, Wang G. Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD). J Med Chem. 2016 09 08; 59(17):8134-40.
    View in: PubMed
    Score: 0.139
  3. Huang TL, Bacchi CJ, Kode NR, Zhang Q, Wang G, Yartlet N, Rattendi D, Londono I, Mazumder L, Vanden Eynde JJ, Mayence A, Donkor IO. Trypanocidal activity of piperazine-linked bisbenzamidines and bisbenzamidoxime, an orally active prodrug. Int J Antimicrob Agents. 2007 Dec; 30(6):555-61.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support